Prediction of adverse maternal and perinatal outcomes in preeclampsia based on B-type natriuretic peptide: a retrospective study

Hong, Haijie; Zhang, Lei; Hong, Fanzhen; Sun, Wenjuan; Dong, Lihua; Li, Mingjiang

doi:10.21037/apm-21-2981

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior studies have shown that natriuretic peptide levels remain stable throughout pregnancy under normal conditions, whereas patients with preeclampsia have a significant increase throughout pregnancy ( 5 , 6 ). Furthermore, elevated natriuretic peptide levels have been associated with increased adverse perinatal outcomes ( 7 ). While natriuretic peptide levels can vary depending on several factors such as age, a normal value within a healthy individual below the age of 50 is considered <100 pg/mL for b-type natriuretic peptide and <450 pg/mL for NT-proBNP due to its longer half-life ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Natriuretic peptide biomarkers in the imminent development of preeclampsia

Marek-Iannucci¹,

Oliveros²,

Brailovsky³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Preeclampsia is the most common cause of morbidity and mortality in pregnancy, the incidence being significantly higher in low-income countries with reduced access to health care. Women with preeclampsia are at a higher risk of developing cardiovascular disease with a poorer long-term outcome. Early recognition and treatment are key to improving short- and long-term outcomes. Approximately 3%–5% of pregnant women will develop preeclampsia, with potentially fatal outcomes. Despite ongoing research, the exact pathophysiologic mechanism behind its development remains unclear. In this brief report, we describe the potential role of natriuretic peptides as biomarkers in the imminent development of preeclampsia. In a retrospective manner, we analyzed changes in the left ventricular ejection fraction and left atrial volume and increases in natriuretic peptide in correlation with the development of preeclampsia. We found that three out of four patients developed a significant increase in natriuretic peptide, which correlated with the development of preeclampsia and/or peripartum cardiomyopathy. Significant increases in natriuretic peptides around the time of delivery might be a marker for the imminent development of preeclampsia. Close monitoring of natriuretic peptide levels in the peripartum period could give important insight into the imminent development of preeclampsia in high-risk patients. Close follow-up in specialized cardio-obstetric clinics is highly recommended.

show abstract

Section: Introductionmentioning

confidence: 99%